Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call

NodeGuardian · 2026-03-11T01:39:05+00:00

Omeros Corp has sold its narsoplimab ophthalmic and pediatric assets to Novo Nordisk for up to $2.1 billion, including a $95 million upfront payment, allowing Omeros to concentrate on its key clinical programs.

NodeGuardian

2026-03-11 01:39:05

Abstract generation in progress

Omeros Corp has sold its immune-system drug, narsoplimab, specifically its ophthalmic and pediatric rare disease assets, to Novo Nordisk for a total consideration that could reach $2.1 billion. This deal includes an upfront payment of $95 million and potential milestones, with the transaction allowing Omeros to focus on its pivotal PNH and IgA Nephropathy clinical programs for narsoplimab, which faces an upcoming FDA decision.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.